Emzahh is an AB-rated generic equivalent of Ortho Micronor.
Experts discuss strategies to reduce the maternal mortality gap by implementing implicit bias training and reevaluating clinical guidelines and algorithms.
Mifepristone is a progestin antagonist indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation.
ACOG experts provide actionable steps to reduce the maternal mortality crisis in the US, particularly among minority populations.
Researchers sought to investigate whether health care providers investigated heavy menstrual bleeding as a potential symptom of an underlying bleeding disorder.
Brexafemme is an oral antifungal agent representing a novel therapeutic class of structurally-distinct glucan synthase inhibitors known as triterpenoids.
Researchers sought to determine whether there was a link between abnormal menstrual bleeding and treatment with anticoagulants for VTE.
The approval was based on additional efficacy data from the ACCESS IUS trial.
Case involving a 2-rod subdermal contraceptive implant mistaken for a 1-rod device demonstrates the importance of delivering culturally competent care.
Authors describe the perspectives of patients and prescribing clinicians regarding the use of antidepressants during pregnancy.
The product was granted approval through the accelerated approval pathway in 2011.
Researchers explored the fertility, contraception, and reproductive health care needs of premenopausal women with early stage breast cancer.
Data from the large-scale SWAN study suggest a rethinking of HDL as beneficial for women in late perimenopause and postmenopause.
Researcher identifies inflammatory foods linked to menstrual pain in teenagers.
Topline results were announced from a phase 3 trial evaluating EVO100 for the prevention of chlamydia and gonorrhea infection in women.
How does early natural menopause affect lung health, aging, and mortality in women who smoke?
In a small study, tadalafil, a PDE5 inhibitor used to treated erectile dysfunction, significantly decreased opening urethral pressure in healthy women.
Fezolinetant is an investigational, nonhormonal selective neurokinin-3 receptor antagonist.
By the end of the 8th year, Mirena should be removed and replaced at the time of removal with a new system if continued use is desired.
Researchers sought to investigate the association between women with laparoscopically confirmed endometriosis and the risk for stroke.